PROK
ProKidney Corp. NASDAQ$1.88
Mkt Cap $544.3M
52w Low $0.54
20.3% of range
52w High $7.13
50d MA $2.04
200d MA $2.40
P/E (TTM)
-3.7x
EV/EBITDA
-3.6x
P/B
0.9x
Debt/Equity
0.0x
ROE
6.8%
P/FCF
-2.2x
RSI (14)
—
ATR (14)
—
Beta
1.86
50d MA
$2.04
200d MA
$2.40
Avg Volume
874.9K
About
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies o…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.16 | -0.14 | +12.5% | 2.08 | -1.0% | -6.2% | -7.2% | -6.7% | -13.9% | -12.0% | — |
| Nov 10, 2025 | AMC | -0.12 | -0.12 | +0.0% | 2.70 | +3.0% | +3.7% | -0.7% | -15.6% | -10.7% | -16.7% | — |
| Aug 12, 2025 | AMC | -0.14 | -0.13 | +7.1% | 2.24 | +0.4% | +5.8% | +8.0% | +5.4% | +13.4% | +4.0% | — |
| May 12, 2025 | AMC | -0.16 | -0.13 | +18.8% | 0.75 | +1.4% | +15.8% | +2.8% | +13.3% | +7.5% | +7.8% | — |
| Mar 17, 2025 | AMC | -0.14 | -0.17 | -21.4% | 1.04 | -1.0% | -6.8% | -4.7% | -9.4% | -7.7% | -1.9% | — |
| Nov 12, 2024 | AMC | -0.14 | -0.14 | +0.0% | 2.05 | +3.4% | +1.0% | +4.9% | -17.1% | -19.0% | -12.2% | — |
| Aug 9, 2024 | AMC | -0.17 | -0.16 | +5.9% | 2.18 | +5.5% | -4.6% | +4.1% | +4.6% | +9.6% | +10.1% | — |
| May 10, 2024 | AMC | -0.25 | -0.16 | +36.0% | 2.81 | +3.2% | +9.6% | +46.6% | +39.5% | +34.9% | +44.5% | — |
| Mar 21, 2024 | AMC | -0.19 | -0.09 | +52.6% | 1.37 | +1.5% | +2.2% | +5.1% | +16.1% | +14.6% | +19.7% | — |
| Nov 14, 2023 | AMC | -0.19 | -0.18 | +5.3% | 1.52 | -2.0% | -8.6% | -19.1% | -20.4% | +15.8% | +22.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 15 | UBS | Maintains | Buy → Buy | — | $3.69 | $4.25 | +15.2% | -8.7% | +1.1% | -4.6% | -14.6% | -12.7% |
| Jul 14 | Guggenheim | Maintains | Buy → Buy | — | $4.54 | $4.78 | +5.3% | -18.7% | -25.8% | -17.8% | -22.5% | -30.6% |
| Jul 9 | Citigroup | Maintains | Buy → Buy | — | $3.73 | $5.81 | +55.8% | +16.4% | +38.9% | +21.7% | -1.1% | -9.7% |
| Jun 30 | BofA Securities | Downgrade | Neutral → Underperform | — | $0.67 | $0.64 | -3.8% | -11.5% | -15.5% | -13.5% | -4.7% | -9.3% |
| Sep 4 | BofA Securities | Maintains | Neutral → Neutral | — | $2.40 | $2.31 | -3.8% | -9.2% | -1.2% | -2.9% | -0.4% | +0.4% |
| Jun 10 | Jefferies | Maintains | Buy → Buy | — | $3.19 | $3.31 | +3.8% | -5.3% | -24.1% | -6.3% | -6.9% | -14.4% |
| May 29 | BofA Securities | Maintains | Neutral → Neutral | — | $3.71 | $3.70 | -0.3% | +6.7% | +13.2% | -6.2% | -18.3% | -13.5% |
| Jan 2 | BofA Securities | Downgrade | Buy → Neutral | — | $1.78 | $1.74 | -2.2% | -3.9% | -15.7% | -15.2% | -18.0% | -16.9% |
| Dec 21 | Jefferies | Maintains | Buy → Buy | — | $7.30 | $7.45 | +2.0% | +3.2% | +1.6% | -10.5% | -15.8% | -25.1% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.55 | $10.65 | +0.9% | +0.9% | +7.9% | +6.2% | +2.7% | -0.9% |
Recent Filings
8-K
Unknown — 8-K Filing
ProKidney's positive Phase 2 results and FDA accelerated approval pathway alignment suggest potential faster commercialization, which could significantly reduce execution risk and create substantial shareholder value if regulatory approvals proceed as planned.
Mar 18
8-K · 8.01
!! High
ProKidney Corp. Class A -- 8-K 8.01: Material Event / Announcement
I need more information to complete this task. The summary appears to be incomplete—it cuts off mid-sentence at "The information set forth in the second paragraph of" without specifying what announcement or material event occurred.
Could you provide the complete summary of the filing?
Feb 2
Data updated apr 26, 2026 8:47pm
· Source: massive.com